Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. reported a net loss of $303.3 million for fiscal year 2025, with no collaboration revenue. The company incurred significant operating expenses totaling $326.2 million, primarily driven by research and development costs of $267.1 million and general and administrative expenses of $59.1 million. Other income of $22.9 million partially offset the operating loss. The company's balance sheet remains strong with total assets of $937.9 million, including $357.3 million in cash and cash equivalents and $568.8 million in marketable securities. Total liabilities were minimal at $59.8 million, resulting in stockholders' equity of $878.1 million. Cash flow from operations was negative $249.1 million, while financing activities provided $702.2 million primarily from stock offerings. The company's accumulated deficit increased to $1.14 billion, reflecting continued investment in research and development activities.

Key Takeaways